Article
Aida Pharmaceuticals Acquires Majority Stake in Shanghai Qiaer Bio-Technology
Author(s):
Aida Pharmaceuticals (Hangzhou, China) has completed its acquisition of majority control of Shanghai Qiaer Bio-Technology Co., Ltd (Shanghai, China).
Aida Pharmaceuticals (Hangzhou, China) has completed its acquisition of majority control of Shanghai Qiaer Bio-Technology Co., Ltd (Shanghai, China). Qiaer Bio-Technology’s flagship drug, Rh-Apo2L, a gene drug developed to treat various forms of cancer, just completed Phase 1 clinical trials.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Videos
Related Content
